December 10, 2020

Safety, efficacy of BNT162b2 mRNA (Pfizer/BioNTech) COVID-19 vaccine

By: Judy Mathias

Editor's Note

This study reports the safety and efficacy findings of the phase 2 and phase 3 parts of the clinical trial of the BNT162b2 mRNA (Pfizere/BioNTech) vaccine in preventing COVID-19 in persons 16 years of age or older. These results are the basis for an application for emergency use authorization from the Food and Drug Administration.

A total of 43,448 participants were randomized to receive a two-dose regimen of injections—21,720 with the vaccine and 21,728 with a placebo.

Sponsored Message

Of 10 cases of severe COVID-19 with onset after the first dose, 9 occurred in placebo recipients and 1 occurred in a vaccine recipient.

There were 8 cases of COVID-19 in vaccine recipients with onset at least 7 days after receiving the second dose and 162 cases of COVID-19 in those who received a second dose of the placebo.

Similar vaccine efficacy was found across subgroups defined by age, gender, race, ethnicity, body-mass index, and presence of coexisting conditions.

The safety profile of the vaccine included short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in both groups.

The findings show that a two-dose regimen of the vaccine conferred 95% protection against COVID-19, and safety over a median of 2 months was similar to that of other viral vaccines, the researchers say.


Sign Up For OR a.m.
Sign up for the free OR a.m. eLetter to get news like this in your inbox every morning!

OR Manager Jobs
Live chat by BoldChat